Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 -3.87%84 Days Payable is 55.37 as of Dec. 2025, which is 9% above its 10-year median of 50.75. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$33.93 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 925 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 71.89% on this metric.
The historical rank and industry rank for Synmosa Biopharma's Days Payable or its related term are showing as below:
ROCO:4114'
s Days Payable Range Over the Past 10 Years
Min: 40.44 Med: 50.75 Max: 57.38
Current: 54.75
During the past 13 years, Synmosa Biopharma's highest Days Payable was 57.38. The lowest was 40.44. And the median was 50.75.
ROCO:4114's Days Payable is ranked worse than 71.89% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs ROCO:4114: 54.75
Synmosa Biopharma's Days Payable
increased
from Dec. 2024 (49.79) to Dec. 2025 (55.37).
It may suggest that Synmosa Biopharmadelayed paying its suppliers.
Synmosa Biopharma Days Payable Related Terms
Synmosa Biopharma Days Payable Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Synmosa Biopharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synmosa Biopharma (ROCO:4114) has a Days Payable of 55.37 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Synmosa Biopharma and its competitors. This is near median its historical median of 50.75. Over the past decade, Synmosa Biopharma's Days Payable has ranged from 40.44 to 57.38. According to the industry distribution chart, Synmosa Biopharma ranks #665 out of 925 companies in the Drug Manufacturers industry, placing it in the top 71.9%.
Is Synmosa Biopharma's Days Payable too high?
Synmosa Biopharma's current Days Payable of 55.37 is near median its 10-year median of 50.75. Over the past 10 years, this metric has ranged from a low of 40.44 to a high of 57.38. The Drug Manufacturers industry median Days Payable is 90.38. Synmosa Biopharma's value of 55.37 is 38.7% below this industry median. Based on the distribution chart, Synmosa Biopharma ranks #665 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #665 out of 925 companies for Days Payable. This places Synmosa Biopharma in the lower half of its industry. The industry median Days Payable is 90.38. Synmosa Biopharma's value of 55.37 is 38.7% below this benchmark. Historically, Synmosa Biopharma's own Days Payable has ranged from 40.44 to 57.38 over the past decade. While the company's 10-year median is 50.75 vs. the industry median of 90.38, Synmosa Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current Days Payable of 55.37 is 38.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Days Payable is 55.37, which is near median its own 10-year median of 50.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.93, compared to a current price of NT$29.30 — trading 13.6% below its estimated fair value. The current Days Payable is 55.37, which is near median its 10-year median of 50.75 and 38.7% below the Drug Manufacturers industry median of 90.38. Synmosa Biopharma's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Days Payable is 55.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.30 is trading 13.6% below its estimated GF Value™ of NT$33.93.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
Days Payable: 55.37 (near median its 10-year median of 50.75)
GF Value™: NT$33.93 vs. price of NT$29.30 (13.6% below fair value)
Industry Position: 38.7% below the Drug Manufacturers median (#665 of 925)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
